← Back to Search

PSMA PET/CT Scan for Prostate Cancer

Phase 3

Recruiting

Research Sponsored by University of Alberta

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2.5 hours after tracer injection

Awards & highlights

Study Summary

This trial will test if 18F-PSMA-1007 PET/CT imaging is safe and effective in adults with prostate cancer.

Who is the study for?

This trial is for adults with prostate cancer who've had surgery or other treatments like radiotherapy, and now have rising PSA levels or high-risk features indicating possible metastatic disease. It's also open to those where a PET/CT scan might help in their care as decided by certain specialists in Alberta.Check my eligibility

What is being tested?

The study tests the safety and effectiveness of a new imaging tracer called 18F-PSMA-1007 used in PET/CT scans. It aims to improve detection of prostate cancer spread, especially evaluating non-specific bone lesions to see if they're benign or malignant.See study design

What are the potential side effects?

Possible side effects include reactions at the injection site, general discomfort post-injection, and any delayed adverse events within a week after receiving the tracer which participants are instructed to report.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2.5 hours after tracer injection

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2.5 hours after tracer injection

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2.5 hours after tracer injection for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Non-specific bone lesion assessment (NSBLs)

Safety - delayed

Safety - immediate

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: 18F-PSMA-1007Experimental Treatment1 Intervention

18F-PSMA-1007, 4 MBq/kg (max 400 MBq; +/- 15%), intravenous, single dose

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of AlbertaLead Sponsor

889 Previous Clinical Trials

382,377 Total Patients Enrolled

9 Trials studying Prostate Cancer

2,754 Patients Enrolled for Prostate Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has 18F-PSMA-1007 secured regulatory authorization from the FDA?

"There is extant clinical data affirming the safety of 18F-PSMA-1007, so our team at Power rated it a 3. This rating reflects that this trial has reached Phase 3 status and thus there are multiple rounds of evidence supporting its efficacy and security."

Answered by AI

What is the upper limit to participant enrollment in this medical research?

"Indeed, according to information accessible on clinicaltrials.gov, this scientific investigation is presently recruiting participants. The study was initially advertised on July 25th 2023 and most recently updated September 2nd 2023; 2800 patients are sought from 1 location for the trial."

Answered by AI

Are there any vacancies left in this medical experiment for participants?

"Data posted on clinicaltrials.gov reveals that this medical research is actively recruiting volunteers, with the study having been first published on July 25th 2023 and last updated September 2nd 2023."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028

2023. "18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05520255.